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Thyreos completes seed funding from Invest
Nebraska, strategic angel investors

Thyreos (https://www.thyreosvaccines.com/), a vaccine company that is developing a novel
vaccine platform that protects against a range of herpesviruses, has
announced a $750,000 investment round led by Invest Nebraska with
participation from other local angel investors in the animal health and
veterinary space.
“The rapid completion of our seed round allowed Thyreos to quickly advance the
development of our first vaccine targets. That would not have been possible without the
commitment of Invest Nebraska and our strategic investors," said Thyreos CEO, Eric Zeece.
The Thyreos team includes co-founders Gary Pickard, Ph.D. professor in the School of
Veterinary Medicine at the University of Nebraska-Lincoln, Ekaterina Heldwein, Ph.D. professor
in the Department of Molecular Biology and Microbiology at Tufts University, Gregory Smith,
Ph.D. professor in the department of Microbiology-Immunology at Northwestern University,
and CEO Eric Zeece. The Thyreos R2 platform is a major breakthrough that allows for
production of effective vaccines against many herpesviruses that infect a range of animals
from livestock and companion animals to ourselves. The company’s roadmap includes the
https://innovate.unl.edu/news/thyreos-completes-seed-funding-invest-nebraska-strategic-angel-investors

1/3

4/29/2021

Thyreos completes seed funding from Invest Nebraska, strategic angel investors | Nebraska Innovation Campus

human-health market, but initial commercial opportunities are focused on the animal health
space.
The commercialization of the Thyreos vaccine technology platform will significantly improve
the beef industry’s ability to protect against Infectious Bovine Rhinotracheitis (IBR), which is
an economically significant respiratory disease caused by a herpesvirus. IBR has negative
impacts beyond respiratory issues. It can also decrease milk production and fertility, and often
leads to secondary bacterial infections, which is why an effective vaccine against bovine
herpesvirus would be such an important breakthrough.
Thyreos has joined The Combine (https://www.nebraskacombine.com/), an agriculture technology
incubator located on Nebraska Innovation Campus, a program run by Invest Nebraska in
collaboration with the Nebraska Department of Economic Development. Current incubator
companies (https://www.nebraskacombine.com/companies) also in the cattle industry include Corral
Technologies, FarmAfield, and Platform Cattle.
“We are pleased to be a part of the Combine. In addition to offering proximity to other
emerging agri-food technologies and companies, the program provides us with unique
resources and contacts that have helped Thyreos to validate market assumptions and
advance product development efforts,” said Thyreos Co-Founder Gary Pickard.
“Nebraska is the leader in not only beef production but also the technology and innovation
that will define the next generation of cattle operations around the world. We are excited to
play a small part in Thyreos," said Invest Nebraska CEO Dan Hoffman.
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